Brawn Biotech

{
  "main_header": {
    "sid": 479596,
    "name": "Brawn Biotech",
    "stock_name": "Brawn Biotech",
    "full_name": "Brawn Biotech Ltd",
    "name_url": "stocks-analysis/brawn-biotech",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 0,
    "country_id": 34,
    "currency": "INR",
    "cmp": "19.80",
    "chg": -1,
    "chgp": "-4.81%",
    "dir": -1,
    "prev_price": "20.80",
    "mcapval": "6.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 530207,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 49,
    "indexname": "India SENSEX",
    "isin": "INE899B01015",
    "curr_date": "May 06",
    "curr_time": "",
    "bse_nse_vol": "2.51 k",
    "exc_status": "Active",
    "traded_date": "May 06, 2026",
    "traded_date_str": "2026 05 06",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/brawn-biotech-479596-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Brawn Biotech Ltd Upgraded to Sell on Technical Improvements Despite Lingering Fundamental Challenges",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/brawn-biotech-ltd-upgraded-to-sell-on-technical-improvements-despite-lingering-fundamental-challenges-3948302",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/BrawnBiotechLtd_mojoScore_3948302.png",
        "date": "2026-04-16 08:04:44",
        "description": "Brawn Biotech Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Strong Sell to Sell as of 15 Apr 2026. This change reflects a nuanced shift driven primarily by technical indicators improving to mildly bullish territory, even as fundamental and valuation concerns persist. The stock’s recent price performance and financial results provide a mixed picture that investors should carefully analyse."
      },
      {
        "title": "Brawn Biotech Ltd Downgraded to Strong Sell Amid Technical and Fundamental Weaknesses",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/brawn-biotech-ltd-downgraded-to-strong-sell-amid-technical-and-fundamental-weaknesses-3931226",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/BrawnBiotechLtd_mojoScore_3931226.png",
        "date": "2026-04-03 08:01:41",
        "description": "Brawn Biotech Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has been downgraded from a Sell to a Strong Sell rating as of 2 April 2026. This revision reflects a deterioration across multiple key parameters including technical indicators, valuation metrics, financial trends, and overall quality assessment. The downgrade comes amid a sharp decline in share price and persistent operational challenges, signalling heightened risk for investors."
      },
      {
        "title": "Brawn Biotech Ltd Downgraded to Strong Sell Amid Technical and Fundamental Concerns",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/brawn-biotech-ltd-downgraded-to-strong-sell-amid-technical-and-fundamental-concerns-3895734",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/BrawnBiotechLtd_mojoScore_3895734.png",
        "date": "2026-03-17 08:03:20",
        "description": "Brawn Biotech Ltd has seen its investment rating downgraded from Sell to Strong Sell as of 16 Mar 2026, reflecting a deterioration in its technical outlook and persistent fundamental challenges. Despite some positive quarterly financial results, the company’s long-term growth trajectory and valuation metrics remain concerning, prompting a reassessment of its investment appeal within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Brawn Biotech Ltd Downgraded to Strong Sell Amid Mixed Financial and Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/brawn-biotech-ltd-downgraded-to-strong-sell-amid-mixed-financial-and-technical-signals-3843556",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/BrawnBiotechLtd_mojoScore_3843556.png",
        "date": "2026-02-17 08:05:12",
        "description": "Brawn Biotech Ltd has seen its investment rating downgraded from Sell to Strong Sell as of 16 Feb 2026, reflecting a complex interplay of financial improvements and persistent fundamental weaknesses. Despite positive quarterly financial trends, the company’s valuation, long-term growth prospects, and technical indicators paint a cautious picture for investors navigating the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Brawn Biotech Ltd Rating Upgraded to Sell Amid Mixed Technical and Financial Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/brawn-biotech-ltd-rating-upgraded-to-sell-amid-mixed-technical-and-financial-signals-3834249",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/BrawnBiotechLtd_mojoScore_3834249.png",
        "date": "2026-02-12 08:03:17",
        "description": "Brawn Biotech Ltd’s investment rating has been upgraded from Strong Sell to Sell, reflecting a modest improvement in its technical outlook despite persistent fundamental challenges. The company’s overall Mojo Score now stands at 33.0, signalling cautious investor sentiment amid weak financial trends and valuation concerns. This article analyses the four key parameters—Quality, Valuation, Financial Trend, and Technicals—that influenced this rating revision."
      },
      {
        "title": "Brawn Biotech Ltd Downgraded to Strong Sell Amid Weak Fundamentals and Technical Setbacks",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/brawn-biotech-ltd-downgraded-to-strong-sell-amid-weak-fundamentals-and-technical-setbacks-3827910",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/BrawnBiotechLtd_mojoScore_3827910.png",
        "date": "2026-02-09 08:02:11",
        "description": "Brawn Biotech Ltd has been downgraded from a Sell to a Strong Sell rating by MarketsMOJO as of 6 February 2026, reflecting deteriorating technical indicators and persistently weak financial fundamentals. The company’s Mojo Score has slipped to 23.0, signalling heightened risk for investors amid sideways technical trends and disappointing long-term performance metrics."
      }
    ],
    "total": 419,
    "sid": "479596",
    "stock_news_url": "https://www.marketsmojo.com/news/brawn-biotech-479596"
  },
  "announcements": [
    {
      "caption": "Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A",
      "datetime": "13-Apr-2026",
      "details": "<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Brawn Biotech Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L74899DL1985PLC022468</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>NA</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: PRIYANKA SHARMA <br/> Designation: COMPANY SECRETARY AND COMPLIANCE OFFICER <br/> EmailId: solution@brawnbiotech.com</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: RATI GARG <br/> Designation: CHIEF FINANCIAL OFFICER <br/> EmailId: srmgraccounts@brawnlabs.in</div> </div> <div> <br/> Date: 13/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>",
      "source": "BSE"
    },
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "07-Apr-2026",
      "details": "Certificate under Reg 74(5) of SEBI (DP) Regulations 2018",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for ANNOUNCEMENT UNDER REGULATION 30 OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) 2015",
      "datetime": "25-Mar-2026",
      "details": "Appointment of Internal Auditors and Secretarial Auditor for FY 2025-26.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Brawn Biotech Ltd has declared <strong>10%</strong> dividend, ex-date: 12 Sep 18",
          "dt": "2018-09-12",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Brawn Biotech Ltd Upgraded to Sell on Technical Improvements Despite Lingering Fundamental Challenges

2026-04-16 08:04:44

Brawn Biotech Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Strong Sell to Sell as of 15 Apr 2026. This change reflects a nuanced shift driven primarily by technical indicators improving to mildly bullish territory, even as fundamental and valuation concerns persist. The stock’s recent price performance and financial results provide a mixed picture that investors should carefully analyse.

Read full news article

Brawn Biotech Ltd Downgraded to Strong Sell Amid Technical and Fundamental Weaknesses

2026-04-03 08:01:41

Brawn Biotech Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has been downgraded from a Sell to a Strong Sell rating as of 2 April 2026. This revision reflects a deterioration across multiple key parameters including technical indicators, valuation metrics, financial trends, and overall quality assessment. The downgrade comes amid a sharp decline in share price and persistent operational challenges, signalling heightened risk for investors.

Read full news article

Brawn Biotech Ltd Downgraded to Strong Sell Amid Technical and Fundamental Concerns

2026-03-17 08:03:20

Brawn Biotech Ltd has seen its investment rating downgraded from Sell to Strong Sell as of 16 Mar 2026, reflecting a deterioration in its technical outlook and persistent fundamental challenges. Despite some positive quarterly financial results, the company’s long-term growth trajectory and valuation metrics remain concerning, prompting a reassessment of its investment appeal within the Pharmaceuticals & Biotechnology sector.

Read full news article

Brawn Biotech Ltd Downgraded to Strong Sell Amid Mixed Financial and Technical Signals

2026-02-17 08:05:12

Brawn Biotech Ltd has seen its investment rating downgraded from Sell to Strong Sell as of 16 Feb 2026, reflecting a complex interplay of financial improvements and persistent fundamental weaknesses. Despite positive quarterly financial trends, the company’s valuation, long-term growth prospects, and technical indicators paint a cautious picture for investors navigating the Pharmaceuticals & Biotechnology sector.

Read full news article

Brawn Biotech Ltd Rating Upgraded to Sell Amid Mixed Technical and Financial Signals

2026-02-12 08:03:17

Brawn Biotech Ltd’s investment rating has been upgraded from Strong Sell to Sell, reflecting a modest improvement in its technical outlook despite persistent fundamental challenges. The company’s overall Mojo Score now stands at 33.0, signalling cautious investor sentiment amid weak financial trends and valuation concerns. This article analyses the four key parameters—Quality, Valuation, Financial Trend, and Technicals—that influenced this rating revision.

Read full news article

Brawn Biotech Ltd Downgraded to Strong Sell Amid Weak Fundamentals and Technical Setbacks

2026-02-09 08:02:11

Brawn Biotech Ltd has been downgraded from a Sell to a Strong Sell rating by MarketsMOJO as of 6 February 2026, reflecting deteriorating technical indicators and persistently weak financial fundamentals. The company’s Mojo Score has slipped to 23.0, signalling heightened risk for investors amid sideways technical trends and disappointing long-term performance metrics.

Read full news article

View All News